Get started
Nurexone Biologic IncNurexone Biologic IncNurexone Biologic Inc

Nurexone Biologic Inc

No trades
OverviewFinancialsNewsCommunitySeasonals

Chart


Full chart

Key stats


Market capitalization
‪30.42 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.077 EUR
Net income (FY)
‪−4.64 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪69.61 M‬
Beta (1Y)
0.17

About Nurexone Biologic Inc


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lior Shaltiel
Website
nurexone.com
Headquarters
Toronto
Founded
2011
IPO date
May 8, 2012
Identifiers
3
ISIN CA67059R1091
CFI code
ESVUFR
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. It focuses on the treatment of spinal cord injury, traumatic brain injury, and other brain and neurological indications. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.

Check out other big names from the same industry as J90.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently asked questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Nurexone Biologic Inc stocks are traded under the ticker J90.
J90 reached its all-time high on Feb 19, 2024 with the price of 0.920 EUR, and its all-time low was 0.104 EUR and was reached on Sep 21, 2023. View more price dynamics on J90 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Nurexone Biologic Inc financials in yearly and quarterly reports right on TradingView.
J90 earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.02 EUR resulting in a 0.00% surprise. The estimated earnings for the next quarter are 0.02 EUR per share. See more details about Nurexone Biologic Inc earnings.
Nurexone Biologic Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
J90 net income for the last quarter is ‪−1.23 M‬ EUR, while the quarter before that showed ‪−1.59 M‬ EUR of net income which accounts for 0.00% change. Track more Nurexone Biologic Inc financial stats to get the full picture.
No, J90 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, J90 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nurexone Biologic Inc stock right from TradingView charts — choose your broker and connect to your account.